Medexus Pharmaceuticals Inc MEDXF

Ebitda Sector Multiple

[nozzpack]

Approximately 13 times for this sector..

https://firstpagesage.com/business/pharmaceutical-company-valuation-ebitda-multiples/

Trailing, MDP had $16.1 million US in Ebitda in 2022 which is about $21 million in CAD equivalent to a fair value of about $275 million CAD or about $13 per share.

MDP had Ebitda of $4,8 million US in Q4 of 2022 on $28 m in Revenur 

Projecting forward for 2023, this would be about $24 million CAD or about $310 million market cap.

That would be about $15 per share assuming no growth in 2023.

As the revenue for Q1 of 2023  is already known to be in excess of $31 million US, $15 per share may be conservative .

So, another peer based valuation shows tremendous upside here,l

[nozzpack]

Ebitda of $6,6 million US  in Q1 which is about $8.2 million in cad. Annualized, Thats about $33 million CAD Ebitda in this sector has a muktiple of 13 times ;( see my recent post ) which computes to a fare market cap of about $410 million cad or about $ 19 per share. This story just keeps getting better with each and every reporting quarter..

[lscfa]

With large o/s debt, EV/ebitda multiples are more relevant.

[nozzpack]

EV to Ebitda is 14.9.. https://www.statista.com/statistics/1030111/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-worldwide/#:~:text=Worldwide%2C%20the%20average%20value%20of,multiple%20of%20approximately%2014.9x.